Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DCL000929

Drug Information
SynonymsSpectrum4_000092; 4-phenylbutyrate; Spectrum5_001003; CID20354; CPD000059104; AC1L2G3A; Spectrum2_001798; BRD-K67102207-236-01-0; I01-3326; DB02000; SAM002264634; NSC 295; .gamma.-Phenylbutyric acid; KBio1_001854; GAMMA-PHENYL-BUTYRIC ACID; FT-0082934; ZINC02037928; BSPBio_002484; AC-3254; Benzenebutanoic acid; AI3-12065; SPBio_001755; gamma-Phenylbutyric acid; TL8001458; AI3-11761; AC1Q5W0X; Phenylbutyrate; Butyric acid, 4-phenyl- (8CI); 4-PHENYLBUTYRIC ACID; NSC295; 2ay7; 4-phenylbutans; Butanoic acid, phenyl ester; Benzenebutyric acid; NCGC00018113-01; Butyric acid, 4-phenyl-; LS-173716; SpecPlus_000814; bmse000701; Spectrum3_000782; EINECS 217-341-8; CID4775; 4-Phenylbutanoic acid; DivK1c_006910; 4346-18-3; KBio2_001811; AKOS002952627; P0643; 1821-12-1; KBioGR_000384; OBKXEAXTFZPCHS-UHFFFAOYSA-; EINECS 224-405-9; InChI=1/C10H12O2/c11-10(12)8-4-7-9-5-2-1-3-6-9/h1-3,5-6H,4,7-8H2,(H,11,12); 2-methyl-1-phenyl-propan-2-amine; AKOS000154540; MLS000069408; AC1L1IXE; KBio2_006947; P21005_ALDRICH; MolPort-000-871-587; Spectrum_001331; MLS001076482; SBB008452; NCI60_002455; 4-PHENYL-BUTANOIC ACID; CHEBI:41500; phenyl butanoate; LS-46421; HDInhib_000004; 1716-12-7 (hydrochloride); NCI60_020145; AC1Q75DT; .omega.-Phenylbutanoic acid; phenyl butyrate; BRD-K67102207-001-02-6; AR-1G4411; AB1001924; CHEMBL1469; KBioSS_001811; SMR000059104; Butyric acid, phenyl ester; omega-Phenylbutanoic acid; AC1Q75DU; 1-Phenylbutyric acid; KBio2_004379; FR-2080; KBio3_001704
CompanyScandinavian Formulae, Ucyclyd, Medicis
IndicationUrea cycle disorders
[ICD9: 270.6   ICD10: E72.2]
Phase II    [1]

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
Canonical SMILESC1=CC=C(C=C1)CCCC(=O)O    
CAS NumberCAS 90315-82-5
PubChem Compound IDCID 4775.
PubChem Substance IDSID 67217.
SuperDrug ATC IDR05DB09
SuperDrug CAS ID000468611;
TargetGABA receptorAgonist[1]
GABA receptorMultitarget[1]
Histone deacetylase Inhibitor[1]
Histone deacetylase Multitarget[1]
Sodium channelBlocker[1]
Sodium channelMultitarget[1]
Ref 1Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links


Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543